What's new
What changed, week by week
Every Monday marked.bio downloads the registry again and compares it with the week before: trials newly registered, trials that started recruiting or stopped, approvals added, and trials that reached their primary completion date.
Follow by RSS Get it by email every week Each biomarker page has its own feed too.
Week to 27 October 2026
8 new trials. Compared with the download of 20 October 2026.
New trials 8
- ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
- TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
- MRD Monitoring in Colorectal Cancer Using ctDNA
- Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer
- A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
- IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
- huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
- Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer
No changes for this biomarker in the weeks shown.
marked.bio keeps the last 12 weeks. A trial that appears on a page because matching improved is not counted as new; only trials first registered since the previous download are.